戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uence (CRS) motif of the v-sis gene product (platelet-derived growth factor-BB).
2  growth factor, fibroblast growth factor, or platelet derived growth factor-BB.
3 re, EC induced migration of 10T1/2 cells via platelet-derived growth factor BB.
4 nsin II, basic fibroblast growth factor, and platelet-derived growth factor BB.
5 dothelial growth medium (EGM-2) or EGM-2 and platelet-derived growth factor BB.
6 tor, vascular endothelial growth factor, and platelet-derived growth factor-BB.
7 fect on AT1-R mRNA down-regulation caused by platelet-derived growth factor-BB.
8 activity showed a surprising specificity for platelet-derived growth factor-BB.
9 ion post-TBI required megakaryocyte-secreted platelet-derived growth factor-BB.
10  IFN-gamma-inducible protein-10, RANTES, and platelet-derived growth factor-BB.
11 nd abolished stimulation of DNA synthesis by platelet-derived growth factor-BB (10 ng/mL) in distal b
12 timulated by angiotensin II, vasopressin and platelet-derived growth factor-BB (4.6-, 2-, and 1.7-fol
13 ells are cultured in EGM-2 supplemented with platelet-derived growth factor-BB (50 ng/mL), they give
14 ssion is needed for VSMC motility induced by platelet-derived growth factor-BB, a receptor tyrosine k
15 fibronectin with epidermal growth factor and platelet-derived growth factor BB and 2% or less fetal c
16 hibiting migration reversed the effect of rh-platelet-derived growth factor-BB and reduced by 40% the
17 t all-trans retinoic acid (atRA) antagonized platelet-derived growth factor-BB and serum-stimulated S
18 ase and G protein-coupled receptor agonists, platelet-derived growth factor-BB and thrombin, respecti
19 ith a peak at 2 hours after stimulation with platelet-derived growth factor-BB and with angiotensin I
20 b cells, but basic fibroblast growth factor, platelet- derived growth factor BB, and IGF-I did not.
21 ctin, growth factors (IGF-I, IGF-I receptor, platelet-derived growth factor-BB, and basic fibroblast
22                           FGF-2, calf serum, platelet-derived growth factor-BB, and phorbol 12-myrist
23 mobilizing mitogens UTP, angiotensin II, and platelet-derived growth factor-BB, and the synergistic i
24 ta1, vascular endothelial growth factor, and platelet-derived growth factor-BB, and this up-regulatio
25 ent NADH/NADPH oxidase inhibitor, on serum-, platelet-derived growth factor BB-, and thrombin-induced
26 tor-2, transforming growth factor-beta1, and platelet-derived growth factor-BB at 2 weeks compared wi
27 th arrest, or various VSMC mitogens, such as platelet-derived growth factor-BB, basic fibroblast grow
28 e graft (CTG) (control) or recombinant human platelet-derived growth factor-BB + beta-tricalcium phos
29 e enhanced by fibroblast growth factor-2 and platelet-derived growth factor-bb, but these peptides di
30  markedly increased migration in response to platelet-derived growth factor-BB, consistent with a mes
31 on of vascular endothelial growth factor and platelet-derived growth factor BB, decreasing hyperglyce
32 ing this fusion protein (PKIalpha-eGFP), but platelet-derived growth factor-BB does not stimulate PKA
33                                 Selection in platelet-derived growth factor BB-enriched medium caused
34  growth factor, epidermal growth factor, and platelet-derived growth factor-BB, factors produced by e
35 ages (TAM), leading to enhanced secretion of platelet-derived growth factor-BB from TAMs, which then
36  study participants, the angiogenic cytokine platelet-derived growth factor BB glycoprotein correlate
37            Two weeks after AMI, increased PB platelet-derived growth factor BB glycoprotein was assoc
38 factor, transforming growth factor-beta, and platelet-derived growth factor-BB had no effect on Thy-1
39  measuring cell migration was employed using platelet derived growth factor-BB homodimer as the chemo
40 expressed selectively in SMC and can inhibit platelet-derived growth factor BB homodimer (PDGF-BB)-in
41 ce showed substantial plasma levels of human platelet-derived growth factor-BB (hPDGF-BB; 855 +/- 347
42  mRNA levels decreased by 80% in response to platelet-derived growth factor-BB in rat aortic smooth m
43 as well as EGF but not by a phorbol ester or platelet-derived growth factor-BB in the VSMC.
44                                              Platelet-derived growth factor BB induced cyclin D1 expr
45                                              Platelet-derived growth factor-BB induced the expression
46 1333 was found to be sufficient in mediating platelet-derived growth factor BB-induced cyclin D1 prom
47 c-Fos, c-Jun, and JunB expression except for platelet-derived growth factor BB-induced ERK2 activatio
48 rtic smooth muscle cell growth but inhibited platelet-derived growth factor BB-induced migration.
49 lation of versican by miR-143 is involved in platelet-derived growth factor BB-induced SMC migration.
50 ium from LTSN cells completely inhibited the platelet-derived growth factor-BB-induced migration of n
51 lly, troglitazone and 15d-PGJ2 inhibited the platelet-derived growth factor-BB-induced migration of V
52  or growth factors (epidermal growth factor, platelet-derived growth factor-BB, insulin growth factor
53 eta (IL-1beta), tumor necrosis factor-alpha, platelet-derived growth factor-BB, insulin-like growth f
54 (+) fibroblast populations were treated with platelet-derived growth factor-BB, interleukin-1beta, in
55 dothelial growth factor, angiopoietin 1, and platelet-derived growth factor-BB levels observed in tum
56 at recombinant apoE and adiponectin suppress platelet-derived growth factor-BB-mediated proliferation
57 rs, fibroblast growth factor-2, insulin, and platelet-derived growth factor-BB, on keratocyte prolife
58 gation analyses in cultured SMC treated with platelet-derived growth factor BB or oxidized phospholip
59 ASMCs, which had been stimulated with either platelet-derived growth factor-BB or serum, and increase
60 gration and fibronectin synthesis induced by platelet-derived growth factor-BB or TGF-beta2.
61 I but not by basic fibroblast growth factor, platelet-derived growth factor-BB, or transforming growt
62 ltured for up to 7 days in serum-free media, platelet derived growth factor BB (PDGF BB), insulin-lik
63                             The VSMC mitogen platelet derived growth factor-BB (PDGF-BB) induces NFAT
64 h, we demonstrate that two of these pathways-platelet-derived growth factor BB (PDGF BB) and neural p
65       We first identified Shh as a target of platelet-derived growth factor BB (PDGF-BB) and found th
66 ed a fibronectin peptide (P12) that can bind platelet-derived growth factor BB (PDGF-BB) and promote
67                      Growth factors, such as platelet-derived growth factor BB (PDGF-BB) and transfor
68                                              Platelet-derived growth factor BB (PDGF-BB) has been sho
69                                              Platelet-derived growth factor BB (PDGF-BB) induced cycl
70                                              Platelet-derived growth factor BB (PDGF-BB) is a Food an
71 ed in a quiescent phase (G(0)), responded to platelet-derived growth factor BB (PDGF-BB) with non-osc
72 induce mineralization, and then treated with platelet-derived growth factor BB (PDGF-BB).
73 tured SMCs by chronic exposure to hypoxia or platelet-derived growth factor BB (PDGF-BB).
74 AR-2-dependent angiogenesis, in synergy with platelet-derived growth factor BB (PDGF-BB).
75 hemotaxis of VSMCs in response to CCL3 or by platelet-derived growth factor BB (PDGF-BB).
76 eptor or by unrelated growth factors such as platelet-derived growth factor BB (PDGF-BB).
77 eptor or by unrelated growth factors such as platelet-derived growth factor BB (PDGF-BB).
78 ulated by ECFC-derived paracrine factors via platelet-derived growth factor BB (PDGF-BB)/platelet-der
79                                   In RASMCs, platelet-derived growth factor-BB (PDGF) stimulated Bcr
80 cell migration and proliferation, induced by platelet-derived growth factor-BB (PDGF), and to establi
81  fibroblast monolayers for 1 or 6 hours with platelet-derived growth factor-BB (PDGF), fibroblast gro
82                                              Platelet-derived growth factor-BB (PDGF)-induced prolife
83 (-/-)) mice and in C57Bl/6 mice treated with platelet-derived growth factor-BB (PDGF).
84  stimulation of the tips of protrusions with platelet-derived growth factor-BB (PDGF).
85 way in the responses of periodontal cells to platelet-derived growth factor-BB (PDGF).
86 ration was maximized by infusing recombinant platelet-derived growth factor-BB (PDGF-BB) after a mini
87  assess the safety of recombinant human (rh) platelet-derived growth factor-BB (PDGF-BB) and (rh) ins
88                                              Platelet-derived growth factor-BB (PDGF-BB) and insulin-
89 n this study, we localized binding sites for platelet-derived growth factor-BB (PDGF-BB) and nerve gr
90  G protein-coupled receptor (GPCR) agonists, platelet-derived growth factor-BB (PDGF-BB) and thrombin
91 ular proteases, binds growth factors such as platelet-derived growth factor-BB (PDGF-BB) and transfor
92 lated by a wide variety of agents, including platelet-derived growth factor-BB (PDGF-BB) and tumor ne
93 ), which when tethered to a surface acted as platelet-derived growth factor-BB (PDGF-BB) enhancers to
94                                              Platelet-derived growth factor-BB (PDGF-BB) has been dem
95                                              Platelet-derived growth factor-BB (PDGF-BB) has been rep
96 roliferation with fetal calf serum (FCS) and platelet-derived growth factor-BB (PDGF-BB) in human sap
97                                              Platelet-derived growth factor-BB (PDGF-BB) is a potent
98                                              Platelet-derived growth factor-BB (PDGF-BB) is a potent
99                          We report here that platelet-derived growth factor-BB (PDGF-BB) is the major
100  stimulation by glial growth factor (GGF) or platelet-derived growth factor-BB (PDGF-BB) is though to
101                                We found that platelet-derived growth factor-BB (PDGF-BB) mRNA was als
102                 Cells that were treated with platelet-derived growth factor-BB (PDGF-BB) or epidermal
103                                              Platelet-derived growth factor-BB (PDGF-BB) released fro
104                          Here, we found that platelet-derived growth factor-BB (PDGF-BB) secreted by
105 cle cells with 100 microM pravastatin before platelet-derived growth factor-BB (PDGF-BB) stimulation
106                            We here show that platelet-derived growth factor-BB (PDGF-BB) strongly sti
107 sforming growth factor-alpha (TGF-alpha) and platelet-derived growth factor-BB (PDGF-BB) were reduced
108 ulfone (PPSF) with various concentrations of platelet-derived growth factor-BB (PDGF-BB) would stimul
109  factor-binding domains (FN-GFBDs) that bind platelet-derived growth factor-BB (PDGF-BB), a potent fi
110 tate level before and after stimulation with platelet-derived growth factor-BB (PDGF-BB), a potent mi
111 (transforming growth factor-beta (TGF-beta), platelet-derived growth factor-BB (PDGF-BB), and insulin
112 esis target, the receptor tyrosine kinase of Platelet-Derived Growth Factor-BB (PDGF-BB), and to impr
113 ctors, insulin-like growth factor-I (IGF-I), platelet-derived growth factor-BB (PDGF-BB), and transfo
114  enamel matrix derivative (EMD), amelogenin, platelet-derived growth factor-BB (PDGF-BB), EMD+PDGF-BB
115  We tested the hypothesis that codelivery of platelet-derived growth factor-BB (PDGF-BB), which recru
116 ve studied the effect of thiol alkylation on platelet-derived growth factor-BB (PDGF-BB)-induced cell
117 imide, a specific thiol alkylating agent, on platelet-derived growth factor-BB (PDGF-BB)-induced mito
118  the receptor tyrosine kinase (RTK) agonist, platelet-derived growth factor-BB (PDGF-BB)-induced p21C
119 s promote a contractile phenotype, while the platelet-derived growth factor-BB (PDGF-BB)-signalling p
120 rom the culture of fat with ROS or PGZ on i) platelet-derived growth factor-BB (PDGF-BB)-stimulated p
121 l remodeling, we examined its involvement in platelet-derived growth factor-BB (PDGF-BB)-stimulated V
122 lated in response to a physiological ligand, platelet-derived growth factor-BB (PDGF-BB).
123 hat governs chemotaxis of fibroblasts toward platelet-derived growth factor-BB (PDGF-BB).
124 dy-state mRNA levels were also evaluated for platelet-derived growth factor-BB (PDGF-BB).
125 oxide after stimulation by angiotensin II or platelet-derived growth factor-BB (PDGF-BB).
126  with angiotensin II (Ang II, 100 nmol/L) or platelet-derived growth factor-BB (PDGF-BB, 10 ng/mL).
127 cts of SP (10(-7)-10(-11) M) with suboptimal platelet-derived growth factor-BB (PDGF-BB; 5 ng/ml) and
128  growth factor, interleukin 6, angiopoietin, platelet-derived growth factor-BB, placental growth fact
129 amel matrix derivative and recombinant human platelet-derived growth factor-BB plus beta-tricalcium p
130                     In contrast, 5 microg of platelet-derived growth factor-BB protein (n = 2) result
131                   Purified recombinant human platelet-derived growth factor BB (rhPDGF-BB) is a poten
132 tematic review, the use of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) led to gre
133 ate (beta-TCP) + 0.3 mg/ml recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with a bio
134 atrix derivative (EMD) and recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with beta-
135 ting two concentrations of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with beta-
136 rigin (eHAC), infused with recombinant human platelet-derived growth factor-BB (rhPDGF-BB), to augmen
137 strongly inhibits UTP-, angiotensin II-, and platelet-derived growth factor-BB-stimulated COX-2 gene
138 dly, results in dose-dependent inhibition of platelet-derived growth factor-BB-stimulated DNA synthes
139 acquired a mature aortic SMC phenotype after platelet-derived growth factor-BB stimulation.
140 are recruited to developing blood vessels by platelet-derived growth factor BB, support endothelial c
141 s 200 ng of bone morphogenetic protein-2 and platelet-derived growth factor-BB that were eluted over
142 or-BB and reduced by 40% the binding of 125I-platelet-derived growth factor-BB to fibroblast cell sur
143 tation (E730R) completely blocked binding of platelet-derived growth factor-BB to intact alpha2M.
144  fibroblast growth factor (FGF), acidic FGF, platelet-derived growth factor-BB, transforming growth f
145                                Compared with platelet-derived growth factor-BB-treated controls, topi
146                                      Topical platelet-derived growth factor-BB trials have required l
147 ession of the spliced XBP1 or treatment with platelet derived growth factor-BB up-regulated miR-150 e
148               In contrast, the expression of platelet-derived growth factor-BB was decreased in a con
149                                              Platelet-derived growth factor-BB was generally ineffect
150 tors such as tumor necrosis factor-alpha and platelet derived growth factor-BB were also found to inc
151 yte-macrophage colony-stimulating factor and platelet-derived growth factor bb were significantly ele
152  uptake stimulated by another growth factor (platelet-derived growth factor BB) were also observed in
153  of vascular endothelial growth factor-A and platelet-derived growth factor-BB, which are necessary f
154 matory cytokines interferon gamma, IL-1, and platelet-derived growth factor-BB, which are not produce

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top